 |
|
Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent
September 22, 2009Berlin, Germany: Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage.
While a large study last year found that patients lived five weeks longer when the targeted drug cetuximab was added to a particular chemotherapy combination, it has not been clear whether it matters which chemotherapy combination the drug is added to, how its addition affects disease progression and what the exact magnitude of the survival benefit is.
Researchers combined the data from four trials that investigated the addition of cetuximab to various different platinum-based chemotherapy combinations in first-line treatment of advanced non-small cell lung cancer. The findings of the meta-analysis, which included a total of 2,018 patients, were presented in Berlin today (Tuesday 22 September) at Europe's largest cancer congress, ECCO 15 - ESMO 34 [1].
Meta-analyses, which integrate the results of several studies, are important for corroborating the findings of key studies and give a more accurate estimate of a drug's true effects.
"We found that patients who got cetuximab had a 13% lower chance of dying within the three years of follow-up compared with those who got chemotherapy alone," said Professor Jean-Louis Pujol, chair of thoracic oncology at Montpelier Academic Hospital and professor of medicine at Montpelier University in France. "For lung cancer, considering that this disease is very resistant to treatment and that the prognosis is very poor, an improvement of that magnitude is meaningful. It's about the same as what you get from giving chemotherapy after surgery and that's accepted as standard treatment."
The median survival, a more crude measure of the drug's effect on death, was 9.4 months in the chemotherapy alone group and 10.3 months in the chemotherapy plus cetuximab group.
The meta-analysis also uncovered a 10% improvement in progression free survival, which measures the length of time a patient survives before the cancer gets worse. None of the individual studies were powerful enough to identify any effect on this outcome on their own, as it is difficult to observe this in lung cancer because the disease progresses so quickly.
The study also found that patients who received the addition of cetuximab were 48% more likely to experience tumour shrinkage.
"Fewer than 30% of patients with advanced non-small cell lung cancer respond to chemotherapy, so even though adding cetuximab increases the chance by another 48%, pushing the response rate up to about 45%, this shows than non-small lung cancer remains a disease that is very resistant to treatment," Prof Pujol said.
The benefits for all these outcomes were seen across all subtypes of the disease.
Lung cancer is particularly difficult to treat and is the leading cause of cancer death worldwide, killing an estimated 1.31 million people a year. Patients with advanced disease have few treatment options and about 70% of them die within one year of diagnosis. Fewer than two percent survive five years. Platinum-based chemotherapy is the standard treatment.
Non-small cell lung cancer is the most common form of lung cancer and most patients have tumours that over-express the epidermal growth factor receptor (EGFR). Cetuximab belongs to a new class of anti-cancer drugs known as monoclonal antibodies and works by blocking the EGF receptor to interrupt uncontrolled cell division.
Studies of other EGFR blockers have not shown any benefit when they are combined with chemotherapy in first-line treatment of advanced non-small cell lung cancer, although they have been shown to help in second-line treatment. One explanation for why cetuximab has shown benefit in this case while the other drugs targeting the receptor haven't could be because it blocks the receptor in a different location. The drug is currently used to treat metastatic colorectal cancer and head and neck cancer. Frequent side effects include an acne-like rash.
"We now have enough evidence to recommend cetuximab for patients with advanced non-small cell lung cancer and we have confirmation that it doesn't matter what kind of chemotherapy it is used with," Prof Pujol said. "What we now need to investigate is whether this drug could also help at early stages of the disease."
ECCO-the European CanCer Organisation
Meta-analyses, which integrate the results of several studies, are important for corroborating the findings of key studies and give a more accurate estimate of a drug's true effects.
"We found that patients who got cetuximab had a 13% lower chance of dying within the three years of follow-up compared with those who got chemotherapy alone," said Professor Jean-Louis Pujol, chair of thoracic oncology at Montpelier Academic Hospital and professor of medicine at Montpelier University in France. "For lung cancer, considering that this disease is very resistant to treatment and that the prognosis is very poor, an improvement of that magnitude is meaningful. It's about the same as what you get from giving chemotherapy after surgery and that's accepted as standard treatment."
The median survival, a more crude measure of the drug's effect on death, was 9.4 months in the chemotherapy alone group and 10.3 months in the chemotherapy plus cetuximab group.
The meta-analysis also uncovered a 10% improvement in progression free survival, which measures the length of time a patient survives before the cancer gets worse. None of the individual studies were powerful enough to identify any effect on this outcome on their own, as it is difficult to observe this in lung cancer because the disease progresses so quickly.
The study also found that patients who received the addition of cetuximab were 48% more likely to experience tumour shrinkage.
"Fewer than 30% of patients with advanced non-small cell lung cancer respond to chemotherapy, so even though adding cetuximab increases the chance by another 48%, pushing the response rate up to about 45%, this shows than non-small lung cancer remains a disease that is very resistant to treatment," Prof Pujol said.
The benefits for all these outcomes were seen across all subtypes of the disease.
Lung cancer is particularly difficult to treat and is the leading cause of cancer death worldwide, killing an estimated 1.31 million people a year. Patients with advanced disease have few treatment options and about 70% of them die within one year of diagnosis. Fewer than two percent survive five years. Platinum-based chemotherapy is the standard treatment.
Non-small cell lung cancer is the most common form of lung cancer and most patients have tumours that over-express the epidermal growth factor receptor (EGFR). Cetuximab belongs to a new class of anti-cancer drugs known as monoclonal antibodies and works by blocking the EGF receptor to interrupt uncontrolled cell division.
Studies of other EGFR blockers have not shown any benefit when they are combined with chemotherapy in first-line treatment of advanced non-small cell lung cancer, although they have been shown to help in second-line treatment. One explanation for why cetuximab has shown benefit in this case while the other drugs targeting the receptor haven't could be because it blocks the receptor in a different location. The drug is currently used to treat metastatic colorectal cancer and head and neck cancer. Frequent side effects include an acne-like rash.
"We now have enough evidence to recommend cetuximab for patients with advanced non-small cell lung cancer and we have confirmation that it doesn't matter what kind of chemotherapy it is used with," Prof Pujol said. "What we now need to investigate is whether this drug could also help at early stages of the disease."
ECCO-the European CanCer Organisation
Chemotherapy Current Events and Chemotherapy News RSSFertility procedures need not delay breast cancer treatment for younger women
A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.
Drugs to treat anemia in cancer patients linked to thromboembolism
Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center.
For young boys with cancer, testicular tissue banking may be option to preserve fertility
For parents of children with cancer, the hopeful news is that pediatric survival rates have steadily improved for decades. Among the bad news-treatments that enable survival often cause infertility.
FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
First use of antibody and stem cell transplantation to successfully treat advanced leukemia
For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.
New Synthetic Molecules Trigger Immune Response to HIV and Prostate Cancer
Researchers at Yale University have developed synthetic molecules capable of enhancing the body's immune response to HIV and HIV-infected cells, as well as to prostate cancer cells. Their findings, published online in the Journal of the American Chemical Society, could lead to novel therapeutic approaches for these diseases.
Chemo-radiation before prostate removal may prevent cancer recurrence
Researchers in the Oregon Health & Science University Knight Cancer Institute and the Portland Veterans Affairs Medical Center have found a combination of radiation therapy and chemotherapy given before prostate removal is safe and may have the potential to reduce cancer recurrence and improve patient survival.
PMH finding may help some tonsil cancer patients avoid chemotherapy
Clinical researchers at Princess Margaret Hospital (PMH) have confirmed that patients with oropharyngeal squamous cell cancer ("tonsil cancer") harbour a common type of human papilloma virus (HPV16), but also that such cancers are very sensitive to radiation.
Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer
Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results.
More Chemotherapy Current Events and Chemotherapy News Articles
 |
The Chemotherapy Survival Guide: Everything You Need to Know to Get Through Treatment by Judith McKay (Author), Tamera Schacher (Author) The first and second editions of this best-selling guide have already helped thousands of people understand chemotherapy and prepare themselves or their loved ones for treatment. The book is used as the primary chemotherapy patient education tool in outpatient clinics nationwide. This new third edition of The Chemotherapy Survival Guide includes updated information on topics including biotherapy, immunotherapy, nutrition, stress reduction, chemotherapy drugs, and more. Written by experienced oncology nurses Judith McKay and Tamera Schacher, this reassuring, optimistic guide helps readers understand their treatment options and explains in plain English how different types of chemotherapy really work. The book includes detailed advice on how to cope with and alleviate the side... |
 |
Chemotherapy and Radiation For Dummies by Alan P. Lyss (Author), Humberto Fagundes (Author), Patricia Corrigan (Author) An informative, compassionate guide for cancer patients and their loved ones Each year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed advice on how to alleviate and cope with side effects-which range from hair loss to nausea to anemia-and describes how good nutrition, meditation, support groups, and other techniques and resources can help in the recovery process. |
 |
Physicians' Cancer Chemotherapy Drug Manual: 2009 by Edward Chu (Author), Vincent DeVita Jr. (Author) Completely revised and updated for 2009, the Physicians Cancer Chemotherapy Drug Manual is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in the clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalogue of over 100 drugs and commonly used drug regimens both on-and off-label for the treatment of all the major cancers. Special features: Features new drugs: Bendamustine, Ixabepilone, and Nilotinib; Revised to reflect rapid advances in the field, incorporating new drug and treatment strategies; diagrams of drug structures and pathways for each agent; Offers a comprehensive discussion of clinical pharmacology, special considerations, indications, and dosages; Covers... |
 |
Handbook of Cancer Chemotherapy by Roland T. Skeel (Editor) The Seventh Edition of this pocket reference is a practical, disease-focused guide to the best current medical practice in cancer chemotherapy. In easy-to-follow outline format, the book provides complete coverage of the principles of rational chemotherapy, the chemotherapeutic and biotherapeutic agents available, the treatment of specific cancers, and selected aspects of supportive care. Emphasis is on the indications, dosage/schedule, potential toxicities, and safe administration of the drugs and their use in treating specific malignancies. This edition describes seventeen new chemotherapeutic agents, with particular attention to molecular targeted agents. Updated chapters on individual cancers and supportive care provide state-of-the-art treatment recommendations. |
 |
Ensure High Calcium Complete Balanced Nutrition, Ready to Use, Creamy Milk Chocolate Shake, 24- 8 Fluid Ounce Bottles by Ensure Ensure High Protein shakes are packed with 12 grams of high - quailty protein to help build muscles. And when you drink high protein shakes, you‘re getting a delicious source of protein that’s low in cholesterol and saturated fat. |
 |
Questioning Chemotherapy by Ralph W. Moss (Author) A revealing critique of chemotherapy, this book looks objectively at chemo's successes and failures. |
 |
Healthy Eating During Chemotherapy by Jose van Mil (Author) People undergoing chemotherapy often experience changes in appetite and taste. Similar problems frequently arise during radiotherapy, Another common side effect is a sore mouth, making it painful to eat. At the same time, it is vital for their recovery that patients keep their body weight up. This unique cookbook is the first of its kind, offering nutritional advice and delicious recipes to help cancer patients keep on enjoying food while fighting to get better. Devised by a chef and based on medical research, the first section of the book discusses which foods are good to eat and which are not. The second part of the book contains over 160 recipes that have been created to soothe the palate. With chapter titles like Smooth, Crispy, and Soft with a Bite, the recipes focus on the... |
 |
Pocket Guide to Chemotherapy Protocols, Fifth Edition by Edward Chu (Author) An indispensable quick reference for physicians, nurses, and other healthcare providers treating cancer patients! The updated Fifth Edition of the best-selling Pocket Guide to Chemotherapy Protocols is spiral bound and arranged alphabetically by cancer type for easy access, and contains combination as well as selected single-agent regimens for solid tumors and hematologic malignancies. In each case, the regimens selected are based on the published literature and are used in clinical practice in the medical oncology community. Pocket Guide to Chemotherapy Protocols, Fifth Edition, continues the success of previous editions by offering cancer care professionals complete, authoritative information in a convenient format. |
 |
The Chemotherapy & Radiation Therapy Survival Guide (Chemotherapy and Radiation Therapy Survivor's Guide) by Judith McKay (Author), Nancee Hirano (Author) |
 |
Coping with Chemotherapy: Compassionate Advice and Authoritative Information from a Chemotherapy Survivor by Nancy Bruning (Author) After undergoing chemotherapy herself, author Nancy Bruning decided to write a candid and authoritative book to fill the void of information available for patients facing this procedure. In this completely revised, updated, and thoroughly researched edition, she details every step of the process, providing information even doctors neglect to tell their patients, including possible sexual and emotional side effects and ways to combat them. Coping with Chemotherapy is a must-read for anyone battling cancer. |
| © 2009 BrightSurf.com |